Chemical Biology | Research Interests

Name	Email	PhD Program
Schrank, Travis EMAIL PUBLICATIONS	PHD PROGRAM Pathobiology & Translational Science RESEARCH INTEREST Bioinformatics, Biophysics, Cancer Biology, Cancer Signaling & Biochemistry, Chemical Biology, Computational Biology, Evolutionary Biology, Genetics, Genomics, Molecular Biology, Molecular Mechanisms of Disease, Translational Medicine, Virology	I am a surgeon-scientist specialized in head and neck cancers. My goal is to address translationalquestions with genomic data and bioinformatic methods, as well as benchtop experimentation. My clinical practice as a head and neck cancer surgeon also influences my research by helping me seek solutions to problems that will directly inform gaps in the current treatment protocols. I have developed a strong interest in HPV genomics as well as HPV/host genome integrations, as these factors are intrinsically related to transcriptional diversity and patient outcomes in HPV-associated head and neck cancers. Our work has helped to demonstrate that a novel mechanism of HPV-mediated oncogenesis requiring NF-kB activation is present in nearly 50% of oropharyngeal tumors. In this vein, we are aggressively investigating the cellular interplay between the NF-kB pathway and persistent HPV infection, tumor radiation response, NRF2 signaling, and more. Another outgrowth of this work has been investigating APOBEC3B and its non-canonical roles in regulating transcription. Our preliminary work has demonstrated that APOBEC3B has surprisingly strong transcriptional effects in HPV+ HNSCC cells and may promote oncogenesis and tumor maintenance by suppressing the innate immune response and influencing the HPV viral lifecycle. Our group also have a strong interest in translational genomic studies. Our group is working to develop methods that will make gene expression-based biomarkers more successful in the clinic, as well as studying many aspects of genomic alterations that contribute to the development of squamous cell carcinomas.
Chung, Kay WEBSITE EMAIL PUBLICATIONS	PHD PROGRAM Cell Biology & Physiology RESEARCH INTEREST Bioinformatics, Cancer Biology, Cancer Immunology, Cancer Signaling & Biochemistry, Chemical Biology, Computational Biology, Gene Therapy, Immunology, Molecular Biology, Signal Transduction, Systems Biology, Translational Medicine, Virology	The Chung lab is engineering immune cells, particularly T cells, to achieve maximum therapeutic efficacy at the right place and timing. We explore the crossroads of synthetic biology, immunology, and cancer biology. Particularly, we are employing protein engineering, next-gen sequencing, CRISPR screening, and bioinformatics to achieve our objectives: (1) Combinatorial recipes of transcription factors for T cell programming. (2) Technologies for temporal regulation and/or rewiring of tumor and immune signal activation (chemokine, nuclear, inhibitor receptors). (3) Synthetic oncolytic virus for engineering tumor-T cell crosstalk.
Cho, Rae WEBSITE EMAIL PUBLICATIONS	PHD PROGRAM Cell Biology & Physiology RESEARCH INTEREST Cell Biology, Chemical Biology, Developmental Biology, Molecular Mechanisms of Disease, Systems Biology	We study proteases that induce rapid changes in cell morphology, behavior, and identity. We are particularly interested in ones that play a role in myotube formation, muscular dystrophies, rhabdomyosarcoma, and cachexia. Our model systems include C2C12 cells, primary myoblasts, patient-derived iPSCs, and zebrafish. In addition to standard cell biology approaches, we make use of chemical biology and advanced microscopy techniques. Ultimately, we seek to identify a combination of protease inhibitors/activators that can cure musculoskeletal diseases.
Do, Jamie EMAIL	PHD PROGRAM RESEARCH INTEREST Biochemistry, Biophysics, Chemical Biology	“Building on my previous research experience in thiol redox chemistry, enzymology, and protein design, I am eager to delve deeper into the field of macromolecular structure and dynamics as well as chemical biology. For instance, I want to investigate the conformational changes of macromolecules and develop novel small molecule inhibitors for targeted drug delivery. From my current knowledge, the Biochemistry and Biophysics and Pharmaceutical Sciences programs within BBSP will provide the ideal environment for pursuing these research interests. I am also excited about the opportunity to rotate in a lab whose research focus is beyond what I have mentioned.”
Binder, Matt EMAIL	PHD PROGRAM RESEARCH INTEREST Chemical Biology, Drug Discovery, Molecular Medicine	“I would like to use chemical tools to study biological systems and pathways. I am interested in understanding the mechanisms of diseases to find and validate potential drug targets. Hopefully, this knowledge can be used to develop novel therapeutics.”
Budayr, Omar EMAIL	PHD PROGRAM RESEARCH INTEREST Chemical Biology, Drug Delivery, Nanomedicine	“I really love solving biology problems with chemistry which is why I’m attracted to chemical biology. Specifically, discovering novel drug targets and developing novel drugs to treat cancer is really exciting to me. I think a massive limitation of our current drugs is how precisely they can be delivered which is why drug delivery is also exciting to me. Especially things like smart liposomes. They have the ability to reduce toxicity, increase safety and efficacy, and allow protein-based drugs to reach intracellular targets. It exciting to think of a world where powerful drugs have minimal side effects and can treat disease much more aggressively as a result. I spent a lot of time in a lab where we used alphafold to predict G protein coupled receptor structures. Protein based drugs have so many advantages over small molecules and this insane leap in machine learning tools will surely revolutionize structure based small molecule design as well as design of protein therapeutics. Finally, I do not know a ton about the immune system, but I’ve spent this spring/ summer taking notes on immunology lectures I found online and it’s very fascinating to me just how sophisticated and complex it is, especially with immunotherapies being all the rage in cancer treatments the last decade. I think nature has created some of the most eloquent solutions to its problems that there is no use reinventing the wheel. If something as complex and effective as the immune system exists, to me it makes more sense to prime/aid the immune system in attacking cancer. Help nature do the heavy lifting rather than doing it ourselves. This idea is really exciting to me, and I would love to work on projects that relate to the immune system but from a chemical biology / med Chem/ drug delivery perspective rather than being in a pure cell bio lab.”
Kratochvil, Huong WEBSITE EMAIL PUBLICATIONS	PHD PROGRAM Chemistry RESEARCH INTEREST Biophysics, Chemical Biology, Structural Biology	We take inspiration from Nature to build new proteins that guide our understanding of how natural proteins function: we can distill complex natural proteins into simple model proteins where we have exact control over the physicochemical properties of the entire system. Our group combines protein design strategies with biochemistry, biophysics, and structural biology to 1) test mechanistic hypotheses of membrane protein structure and function, and 2) define novel protein-protein interactions in immunology for engineering protein-based therapeutics.
Frankowski, Kevin WEBSITE EMAIL PUBLICATIONS	PHD PROGRAM Pharmaceutical Sciences RESEARCH INTEREST Chemical Biology, Drug Discovery, Translational Medicine	We are inspired by the diversity and complexity found in natural products and use their architecture as both a platform for developing chemical methods and as scaffolds for new molecular tools in chemical biology. We have employed our chemical synthesis skill set to solve emerging challenges facing modern medicine. This has led to ongoing collaborative projects in metastatic cancer, hepatitis C antivirals, dopamine signaling and sigma receptor ligands. Of particular interest is the development of next generation anti-metastasis agents to our recent phase I clinical candidate, metarrestin.
Willson, Tim WEBSITE EMAIL PUBLICATIONS	PHD PROGRAM Pharmaceutical Sciences RESEARCH INTEREST Chemical Biology, Drug Discovery	A unifying goal of my research is the use of chemistry as a tool to illuminate human biology. For over two decades I have led programs to develop potent cell active chemical probes to identify and study the biological function of their target proteins. Starting in 1992 with the orphan nuclear receptors, my lab developed chemical probes to uncover the roles of PPAR, PPAR, LXR, FXR, CAR, and PXR in human physiology. The release of our chemical probes into the public domain supported research across the global scientific community and resulted in multiple drug candidates to treat diseases of human metabolism entering clinical development. I am co-discoverer of the FXR agonist obeticholic acid, which was approved by the FDA in 2016 as a drug for the treatment of Primary Biliary Cholangitis. In 2007, I started a collaboration with the Structural Genomics Consortium (SGC) to discover chemical probes for the enzymes and reader domains involved in epigenetic regulation. Together, we built a consortium with support from public funders and eight pharmaceutical companies that has released over 40 high quality chemical probes into the public domain. We demonstrated that the bromodomain family of acetyl lysine reader domains were highly tractable targets for drug discovery, which led to the development of BRD4 inhibitors for the treatment of various rare cancers. In 2015, I established the first US site of the SGC at the University of North Carolina in Chapel Hill to expand the footprint of open science in US academia. I have assembled a team at SGC-UNC to create chemical tools for understudied (‘dark’) kinases, identify inhibitors of molecular targets that cause rare diseases, and develop chemical probes for proteins associated with neurodegenerative diseases. With support from the NIH Illuminating the Druggable Genome program we assembled a Kinase Chemogenomic Set (KCGS): the largest, highly annotated and publicly available collection of small molecule kinase inhibitors. We used KCGS to identify kinases whose inhibition prevents replication of coronaviruses including SARS-CoV-2. Medicinal chemists at the SGC-UNC are also developing chemical probes within the Med Chem Core of the NIA Target Enablement to Accelerate Therapy Development for Alzheimer’s Disease (TREAT-AD) program at UNC.
Axtman, Alison WEBSITE EMAIL PUBLICATIONS	PHD PROGRAM Pharmaceutical Sciences RESEARCH INTEREST Cell Biology, Cell Signaling, Chemical Biology, Drug Discovery	In my lab, we are exploring the roles that kinases play in neurodegeneration through the creation of high-quality, small molecule tools. Our team designs, synthesizes, and evaluates small molecules capable of kinase modulation, sometimes targeting kinase inhibition and sometimes kinase activation. In order to accomplish our aims, we work closely with X-ray crystallographers within the larger SGC and with biologists, including experts in using stem cells to model neurodegenerative diseases. We seek enthusiastic students with an interest in neuroscience who are willing to learn and apply techniques that span chemistry and biology to better understand and address neurodegeneration.

Research Interest: Chemical Biology